Enfermedades infecciosas y microbiologia clinica最新文献

英文中文

RIME sine rash asociada a infección por Mycoplasma pneumoniae

IF 2.6 4区医学 Q3 INFECTIOUS DISEASES

Enfermedades infecciosas y microbiologia clinica

Pub Date : 2025-03-01 DOI: 10.1016/j.eimc.2024.10.004

Antonio Bustos-Merlo, Ana Peragón-Ortega, Antonio Rosales-Castillo, Pedro Alberto Alarcón-Blanco

引用次数: 0

Complicated malaria caused by Plasmodium falciparum with parasitemia >50%

IF 2.6 4区医学 Q3 INFECTIOUS DISEASES

Enfermedades infecciosas y microbiologia clinica

Pub Date : 2025-03-01 DOI: 10.1016/j.eimc.2024.07.006

Miguel Morante-Ruiz, Cristina Ortega-Portas, Luis José Betancourt-Cuadra, Miguel Górgolas Hernández-Mora

引用次数: 0

Seroprevalence status of vaccine-preventable diseases in migrants living in shelter centers in Barcelona, Spain 居住在西班牙巴塞罗那收容中心的移民中疫苗可预防疾病的血清流行状况

IF 2.6 4区医学 Q3 INFECTIOUS DISEASES

Enfermedades infecciosas y microbiologia clinica

Pub Date : 2025-03-01 DOI: 10.1016/j.eimc.2024.04.005

Carles Rubio Maturana , Marta Guerrero , Maria Casas Claramunt , Susana Nuria Ayala-Cortés , Victoria López , Patricia Martínez-Vallejo , Begoña Treviño , Elena Sulleiro , Juliana Esperalba , Ariadna Rando , Diana Pou , Maria Luisa Aznar , Pau Bosch-Nicolau , Fernando Salvador , Inés Oliveira-Souto , Israel Molina , Núria Serre-Delcor

Introduction

Almost 281 million people were living in a foreign country in 2022, and more than 100 million were displaced because of war conflicts and human right violations. Vaccination coverage of infectious diseases in migrants from some disadvantaged settings could be lower than reception countries populations, consequently seroprevalence studies and better access to vaccination could contribute to reducing these differences.

Methods

A descriptive retrospective cross-sectional study was conducted including migrants, living ≤5 years in the reception country and ≥16 years old, who requested a medical exam between January 1st, 2020 and January 31st, 2021. Seroprevalence assessment was performed, and vaccination was offered to those individuals without immunity to hepatitis B, hepatitis A, varicella, measles, mumps, and rubella.

Results

A total of 315 migrants were attended during the study period. Immunity protection at arrival was 252/296 (85.1%) for measles, 274/295 (92.9%) for rubella, 257/296 (86.8%) for mumps, 264/295 (89.5%) for varicella, 267/313 (85.3%) for hepatitis A, and 104/300 (34.6%) for hepatitis B. The final immunity protection after full vaccination schedules was 278/296 (93.9%) for measles, 287/295 (97.3%) for rubella, 274/296 (92.6%) for mumps, 276/295 (93.6%) for varicella, 280/313 (89.5%) for hepatitis A, and 139/300 (46.3%) for hepatitis B.

Conclusions

The vaccination intervention has increased immunity rates for the studied diseases in the attended migrants in our center, however, such interventions should be maintained to reach local population immunization levels. Moreover, the collaboration between shelter and reference specialized health centers is fundamental to implement such vaccination programs.

{"title":"Seroprevalence status of vaccine-preventable diseases in migrants living in shelter centers in Barcelona, Spain","authors":"Carles Rubio Maturana , Marta Guerrero , Maria Casas Claramunt , Susana Nuria Ayala-Cortés , Victoria López , Patricia Martínez-Vallejo , Begoña Treviño , Elena Sulleiro , Juliana Esperalba , Ariadna Rando , Diana Pou , Maria Luisa Aznar , Pau Bosch-Nicolau , Fernando Salvador , Inés Oliveira-Souto , Israel Molina , Núria Serre-Delcor","doi":"10.1016/j.eimc.2024.04.005","DOIUrl":"10.1016/j.eimc.2024.04.005","url":null,"abstract":"<div><h3>Introduction</h3><div>Almost 281 million people were living in a foreign country in 2022, and more than 100 million were displaced because of war conflicts and human right violations. Vaccination coverage of infectious diseases in migrants from some disadvantaged settings could be lower than reception countries populations, consequently seroprevalence studies and better access to vaccination could contribute to reducing these differences.</div></div><div><h3>Methods</h3><div>A descriptive retrospective cross-sectional study was conducted including migrants, living ≤5 years in the reception country and ≥16 years old, who requested a medical exam between January 1st, 2020 and January 31st, 2021. Seroprevalence assessment was performed, and vaccination was offered to those individuals without immunity to hepatitis B, hepatitis A, varicella, measles, mumps, and rubella.</div></div><div><h3>Results</h3><div>A total of 315 migrants were attended during the study period. Immunity protection at arrival was 252/296 (85.1%) for measles, 274/295 (92.9%) for rubella, 257/296 (86.8%) for mumps, 264/295 (89.5%) for varicella, 267/313 (85.3%) for hepatitis A, and 104/300 (34.6%) for hepatitis B. The final immunity protection after full vaccination schedules was 278/296 (93.9%) for measles, 287/295 (97.3%) for rubella, 274/296 (92.6%) for mumps, 276/295 (93.6%) for varicella, 280/313 (89.5%) for hepatitis A, and 139/300 (46.3%) for hepatitis B.</div></div><div><h3>Conclusions</h3><div>The vaccination intervention has increased immunity rates for the studied diseases in the attended migrants in our center, however, such interventions should be maintained to reach local population immunization levels. Moreover, the collaboration between shelter and reference specialized health centers is fundamental to implement such vaccination programs.</div></div>","PeriodicalId":11608,"journal":{"name":"Enfermedades infecciosas y microbiologia clinica","volume":"43 3","pages":"Pages 139-147"},"PeriodicalIF":2.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141137887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Estudio prospectivo para la detección precoz de carcinoma pulmonar en pacientes con infección por VIH (estudio GESIDA 8815)

IF 2.6 4区医学 Q3 INFECTIOUS DISEASES

Enfermedades infecciosas y microbiologia clinica

Pub Date : 2025-03-01 DOI: 10.1016/j.eimc.2024.03.003

M. Eulalia Valencia , Tatiana Pirogova , Delia Romera , Marta Montero , María Tasías , José Sanz , Alberto Arranz , Jorge Vergas , M. Jesús Tellez , Francisco Fanjul , Antoni Campins , Miguel Cervero , Inmaculada Jarrín , Marta de Miguel , Luz Martín Carbonero , María Yllescas , Juan González

Introduction

Lung cancer (LC) screening detects tumors early. The prospective GESIDA 8815 study was designed to assess the usefulness of this strategy in HIV+ people (PLHIV) by performing a low-radiation computed tomography (CT) scan.

Patients and methods

371 heavy smokers patients were included (> 20 packs/year), > 45 years old and with a CD4+ < 200 mm³ nadir. One visit and CT scan were performed at baseline and 4 for follow-up time annually.

Results

329 patients underwent the baseline visit and CT (CT0) and 206 completed the study (CT1 = 285; CT2 = 259; CT3 = 232; CT4 = 206). All were receiving ART. A total > 8 mm lung nodules were detected, and 9 early-stage PCs were diagnosed (4 on CT1, 2 on CT2, 1 on CT3 and 2 on CT4). There were no differences between those who developed LC and those who did not in sex, age, CD4+ nadir, previous lung disease, family history, or amount of packets/year. At each visit, other pathologies were diagnosed, mainly COPD, calcified coronary artery and residual tuberculosis lesions. At the end of the study, 38 patients quit smoking and 75 reduced their consumption. Two patients died from LC and 16 from other causes (P = .025).

Conclusions

The design of the present study did not allow us to define the real usefulness of the strategy. Adherence to the test progressively decreased over time. The diagnosis of other thoracic pathologies is very frequent. Including smokers in an early diagnosis protocol for LC could help to quit smoking.

{"title":"Estudio prospectivo para la detección precoz de carcinoma pulmonar en pacientes con infección por VIH (estudio GESIDA 8815)","authors":"M. Eulalia Valencia , Tatiana Pirogova , Delia Romera , Marta Montero , María Tasías , José Sanz , Alberto Arranz , Jorge Vergas , M. Jesús Tellez , Francisco Fanjul , Antoni Campins , Miguel Cervero , Inmaculada Jarrín , Marta de Miguel , Luz Martín Carbonero , María Yllescas , Juan González","doi":"10.1016/j.eimc.2024.03.003","DOIUrl":"10.1016/j.eimc.2024.03.003","url":null,"abstract":"<div><h3>Introduction</h3><div>Lung cancer (LC) screening detects tumors early. The prospective GESIDA 8815 study was designed to assess the usefulness of this strategy in HIV+ people (PLHIV) by performing a low-radiation computed tomography (CT) scan.</div></div><div><h3>Patients and methods</h3><div>371 heavy smokers patients were included (>20 packs/year), >45years old and with a CD4+ <200mm<sup>3</sup> nadir. One visit and CT scan were performed at baseline and 4 for follow-up time annually.</div></div><div><h3>Results</h3><div>329 patients underwent the baseline visit and CT (CT0) and 206 completed the study (CT1=285; CT2=259; CT3=232; CT4=206). All were receiving ART. A total >8mm lung nodules were detected, and 9 early-stage PCs were diagnosed (4 on CT1, 2 on CT2, 1 on CT3 and 2 on CT4). There were no differences between those who developed LC and those who did not in sex, age, CD4+ nadir, previous lung disease, family history, or amount of packets/year. At each visit, other pathologies were diagnosed, mainly COPD, calcified coronary artery and residual tuberculosis lesions. At the end of the study, 38 patients quit smoking and 75 reduced their consumption. Two patients died from LC and 16 from other causes (<em>P</em>  <!-->.025).</div></div><div><h3>Conclusions</h3><div>The design of the present study did not allow us to define the real usefulness of the strategy. Adherence to the test progressively decreased over time. The diagnosis of other thoracic pathologies is very frequent. Including smokers in an early diagnosis protocol for LC could help to quit smoking.</div></div>","PeriodicalId":11608,"journal":{"name":"Enfermedades infecciosas y microbiologia clinica","volume":"43 3","pages":"Pages 125-132"},"PeriodicalIF":2.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143527084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Diagnosis of Carrion's disease: A systematic review in South American countries and meta-analysis

IF 2.6 4区医学 Q3 INFECTIOUS DISEASES

Enfermedades infecciosas y microbiologia clinica

Pub Date : 2025-03-01 DOI: 10.1016/j.eimc.2024.11.005

Mauro A.F. Guimarães , Laura A. Xavier , Alice F. Silva , Felipe C.M. Iani , Cecília M.M. Anjos , Cristiane F.O. Scarponi

Bartonella bacilliformis can cause a potentially fatal infection, Carrion's disease. This review synthesized data on the prevalence of this bacterial infection in South American countries. A comprehensive literature search relevant articles (published between 2010 and 2022) was conducted in four databases. Full texts were selected based on PECOTS eligibility and JBI methodological quality. The pooled bacterial infection rate was calculated using a random-effects meta-analysis model. Subgroup and meta-regression analyses were used to investigate statistical heterogeneity. Five studies (covering 717 individuals from Peru and Ecuador) were eligible for meta-analysis. The percentage of seropositive IgG antibodies against B. bacilliformis was 28.21% (95% CI: 6.29–33.39) among healthy Ecuadorian children. In Peru, the pooled bacterial detection rate in symptomatic individuals was 15.60% (95% CI: 4.24–31.98), using molecular tests. Carrion's disease is endemic in the Andean valleys, but a gradual reduction in infection rates among acute febrile patients in Peru has been observed in recent years. Laboratory diagnosis of this infection continues to be neglected in other South American countries. Public managers must plan effective arrangements in primary care services, integrating various technological levels to ensure comprehensive health care.

{"title":"Diagnosis of Carrion's disease: A systematic review in South American countries and meta-analysis","authors":"Mauro A.F. Guimarães , Laura A. Xavier , Alice F. Silva , Felipe C.M. Iani , Cecília M.M. Anjos , Cristiane F.O. Scarponi","doi":"10.1016/j.eimc.2024.11.005","DOIUrl":"10.1016/j.eimc.2024.11.005","url":null,"abstract":"<div><div><em>Bartonella bacilliformis</em> can cause a potentially fatal infection, Carrion's disease. This review synthesized data on the prevalence of this bacterial infection in South American countries. A comprehensive literature search relevant articles (published between 2010 and 2022) was conducted in four databases. Full texts were selected based on PECOTS eligibility and JBI methodological quality. The pooled bacterial infection rate was calculated using a random-effects meta-analysis model. Subgroup and meta-regression analyses were used to investigate statistical heterogeneity. Five studies (covering 717 individuals from Peru and Ecuador) were eligible for meta-analysis. The percentage of seropositive IgG antibodies against <em>B. bacilliformis</em> was 28.21% (95% CI: 6.29–33.39) among healthy Ecuadorian children. In Peru, the pooled bacterial detection rate in symptomatic individuals was 15.60% (95% CI: 4.24–31.98), using molecular tests. Carrion's disease is endemic in the Andean valleys, but a gradual reduction in infection rates among acute febrile patients in Peru has been observed in recent years. Laboratory diagnosis of this infection continues to be neglected in other South American countries. Public managers must plan effective arrangements in primary care services, integrating various technological levels to ensure comprehensive health care.</div></div>","PeriodicalId":11608,"journal":{"name":"Enfermedades infecciosas y microbiologia clinica","volume":"43 3","pages":"Pages 165-171"},"PeriodicalIF":2.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143527088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Enfermedad de Chagas y coinfección por el VIH

IF 2.6 4区医学 Q3 INFECTIOUS DISEASES

Enfermedades infecciosas y microbiologia clinica

Pub Date : 2025-02-01 DOI: 10.1016/j.eimc.2024.09.008

Jesús Fernández Plaza , Javier Guzmán , Sandra Chamorro-Tojeiro , José A. Pérez-Molina

引用次数: 0

Análisis del diagnóstico serológico de la sífilis: una propuesta de mejora

IF 2.6 4区医学 Q3 INFECTIOUS DISEASES

Enfermedades infecciosas y microbiologia clinica

Pub Date : 2025-02-01 DOI: 10.1016/j.eimc.2024.09.010

Javier Gutiérrez Ballesteros , Sonsoles Garcinuño Pérez , Marta Domínguez-Gil González , Silvia Rojo Rello

引用次数: 0

Dalbavancin as sequential therapy in infective endocarditis: Real-life experience in elder and comorbid patients 达巴万星作为感染性心内膜炎的序贯疗法：老年患者和合并症患者的实际经验

IF 2.6 4区医学 Q3 INFECTIOUS DISEASES

Enfermedades infecciosas y microbiologia clinica

Pub Date : 2025-02-01 DOI: 10.1016/j.eimc.2024.04.009

Eduardo Aparicio-Minguijón , Jorge Boán , Antonio Terrón , Carlos Heredia , Cristina Puente , Asunción Pérez-Jacoiste Asín , M. Ángeles Orellana , Laura Domínguez , José Manuel Caro , M. Jesús López-Gude , Eva María Aguilar-Blanco , Andrea Eixerés-Esteve , Francisco López-Medrano

Objectives

This study aimed to evaluate the effectiveness of dalbavancin as sequential therapy in patients with infective endocarditis (IE) due to gram positive bacteria (GPB) in a real-life heterogenous cohort with comorbid patients.

Methods

A single center retrospective cohort study including all patients with definite IE treated with dalbavancin between January 2017 and February 2022 was developed. A 6-month follow-up was performed. The main outcomes were clinical cure rate, clinical and microbiological relapse, 6-month mortality, and adverse effects (AEs) rate.

Results

The study included 61 IE episodes. The median age was 78.5 years (interquartile range [IQR] 63.2–85.2), 78.7% were male, with a median Charlson comorbidity index of 7 (IQR 4–9) points. Overall, 49.2% suffered native valve IE. The most common microorganism was Staphylococcus aureus (26.3%) followed by Enterococcus faecalis (21.3%). The median duration of initial antimicrobial therapy and dalbavancin therapy were 27 (IQR 20–34) and 14 days (IQR 14–28) respectively. The total reduction of hospitalization was 1090 days. The most frequent dosage was 1500 mg of dalbavancin every 14 days (96.7%). An AE was detected in 8.2% of patients, only one (1.6%) was attributed to dalbavancin (infusion reaction). Clinical cure was achieved in 86.9% of patients. One patient (1.6%) with Enterococcus faecalis IE suffered relapse. The 6-month mortality was 11.5%, with only one IE-related death (1.6%).

Conclusion

This study shows a high efficacy of dalbavancin in a heterogeneous real-world cohort of IE patients, with an excellent safety profile. Dalbavancin allowed a substantial reduction of in-hospital length of stay.

{"title":"Dalbavancin as sequential therapy in infective endocarditis: Real-life experience in elder and comorbid patients","authors":"Eduardo Aparicio-Minguijón , Jorge Boán , Antonio Terrón , Carlos Heredia , Cristina Puente , Asunción Pérez-Jacoiste Asín , M. Ángeles Orellana , Laura Domínguez , José Manuel Caro , M. Jesús López-Gude , Eva María Aguilar-Blanco , Andrea Eixerés-Esteve , Francisco López-Medrano","doi":"10.1016/j.eimc.2024.04.009","DOIUrl":"10.1016/j.eimc.2024.04.009","url":null,"abstract":"<div><h3>Objectives</h3><div>This study aimed to evaluate the effectiveness of dalbavancin as sequential therapy in patients with infective endocarditis (IE) due to gram positive bacteria (GPB) in a real-life heterogenous cohort with comorbid patients.</div></div><div><h3>Methods</h3><div>A single center retrospective cohort study including all patients with definite IE treated with dalbavancin between January 2017 and February 2022 was developed. A 6-month follow-up was performed. The main outcomes were clinical cure rate, clinical and microbiological relapse, 6-month mortality, and adverse effects (AEs) rate.</div></div><div><h3>Results</h3><div>The study included 61 IE episodes. The median age was 78.5 years (interquartile range [IQR] 63.2–85.2), 78.7% were male, with a median Charlson comorbidity index of 7 (IQR 4–9) points. Overall, 49.2% suffered native valve IE. The most common microorganism was <span><span>Staphylococcus aureus</span></span> (26.3%) followed by <span><span>Enterococcus faecalis</span></span> (21.3%). The median duration of initial antimicrobial therapy and dalbavancin therapy were 27 (IQR 20–34) and 14 days (IQR 14–28) respectively. The total reduction of hospitalization was 1090 days. The most frequent dosage was 1500mg of dalbavancin every 14 days (96.7%). An AE was detected in 8.2% of patients, only one (1.6%) was attributed to dalbavancin (infusion reaction). Clinical cure was achieved in 86.9% of patients. One patient (1.6%) with <em>Enterococcus faecalis</em> IE suffered relapse. The 6-month mortality was 11.5%, with only one IE-related death (1.6%).</div></div><div><h3>Conclusion</h3><div>This study shows a high efficacy of dalbavancin in a heterogeneous real-world cohort of IE patients, with an excellent safety profile. Dalbavancin allowed a substantial reduction of in-hospital length of stay.</div></div>","PeriodicalId":11608,"journal":{"name":"Enfermedades infecciosas y microbiologia clinica","volume":"43 2","pages":"Pages 86-92"},"PeriodicalIF":2.6,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141415987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Peritonitis bacteriana aguda por Staphylococcus lugdunensis resistente a meticilina

IF 2.6 4区医学 Q3 INFECTIOUS DISEASES

Enfermedades infecciosas y microbiologia clinica

Pub Date : 2025-02-01 DOI: 10.1016/j.eimc.2024.08.010

David Roa Alonso , Víctor Antón Berenguer , Alberto Orejas Gallego , Ricardo Díaz Abad

引用次数: 0

Nuevo secuenciotipo ST6423 de Klebsiella pneumoniae hipervirulenta portador de carbapenemasa OXA-48-like causante de bacteriemia en un paciente inmunocomprometido

IF 2.6 4区医学 Q3 INFECTIOUS DISEASES

Enfermedades infecciosas y microbiologia clinica

Pub Date : 2025-02-01 DOI: 10.1016/j.eimc.2024.08.014

Carmen Palacios Clar, Diego García Martínez de Artola, Julia Alcoba Flórez

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Enfermedades infecciosas y microbiologia clinica

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀